뇌경색 치료 시장 규모, 점유율, 동향 분석 보고서 : 약제 클래스별, 유형별, 유통 채널별, 지역별, 부문 예측(2025-2030년)

Cerebral Infarction Treatment Market Size, Share & Trends Analysis Report By Drug Class (Anticoagulants, Antiplatelets), By Type (Ischemic Stroke), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,515,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,946,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,809,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

뇌경색 치료 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 뇌경색 치료 시장 규모는 2030년까지 205억 1,000만 달러에 달할 것으로 예상되며 2025년부터 2030년까지 7.4%의 연평균 성장률(CAGR)로 성장할 것으로 전망됩니다. 전 세계 인구의 고령화와 고혈압, 당뇨병과 같은 생활 습관 관련 위험 요인의 증가로 인한 허혈성 뇌졸중 유병률의 증가는 뇌경색 치료 시장 확대의 핵심 요인입니다.

2023년 3월 미국 국립의학도서관이 발표한 연구에 따르면 출혈성 뇌졸중은 매년 전체 뇌졸중의 10.0-20.0%를 차지합니다. 미국, 영국, 호주는 8.0-15.0%, 일본과 한국은 18.0-24.0%로 지역별로 발생률이 크게 다릅니다. 출혈성 뇌졸중은 저소득 및 중간 소득 국가와 아시아인에서 특히 더 높은 비율을 보입니다. 또한 뇌졸중 발병률은 남성에서 더 높고 나이가 들수록 증가하며, 특히 아프리카와 아시아 국가에서 출혈성 뇌졸중으로 인한 전 세계적인 부담이 증가하고 있습니다. 고혈압을 효과적으로 관리하면 뇌내출혈(ICH) 발생률이 감소하는 것으로 나타났지만, 고소득 국가에서는 25.0-30.0%, 저소득 지역에서는 30-48%에 이르는 치명률이 여전히 우려되는 수준으로 중환자 치료 효과의 불균형을 드러내고 있습니다.

기술의 발전으로 뇌경색 치료 환경이 크게 개선되고 있습니다. 조직 플라스미노겐 활성화제(tPA)와 같은 혈전용해 요법의 혁신과 기계적 혈전 제거 장치의 개발로 환자 치료 결과가 현저하게 개선되었습니다. 또한 인공지능(AI)이 진단 및 치료 과정에 통합되면서 뇌졸중 치료가 혁신적으로 변화하고 있습니다. 이제 AI 기반 알고리즘은 뇌졸중 위험을 예측하고 치료 전략을 맞춤화하는 데 중요한 역할을 하며, 이는 개인 맞춤형 치료와 전반적인 효능을 개선하는 데 도움이 됩니다. 이러한 발전은 치료의 정확성을 향상시킬 뿐만 아니라 첨단 치료 옵션의 광범위한 채택에도 기여하고 있습니다. 이러한 기술적 발전은 연구 개발에 대한 투자 증가와 함께 뇌경색 치료 시장의 상당한 성장을 견인할 것으로 예상됩니다.

뇌경색 치료 시장 보고서 하이라이트

• 2024년 허혈성 뇌졸중 부문은 높은 유병률, 기술 발전 및 조기 개입에 대한 인식 증가로 인해 78.6%의 가장 큰 점유율을 차지했습니다.
• 조직 플라스미노겐 활성화제(tPA)부문은 입증 된 효능, 광범위한 사용 및 허혈성 뇌졸중 치료에서 중요한 역할로 인해 2024년에 39.2%의 가장 큰 매출 점유율을 확보했습니다.
• 2024년에는 병원 약국 부문이 뇌경색 치료 시장을 독점하여 63.6%의 상당한 판매 점유율을 획득했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 뇌경색 치료 시장의 변수, 동향, 범위

• 시장 계통 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 업계 분석 - Porter's Five Forces 분석
  • PESTLE 분석

제4장 뇌경색 치료 시장 : 약제 클래스별 비즈니스 분석

• 마약 클래스 시장 점유율(2024년, 2030년)
• 마약 클래스 부문 대시보드
• 시장 규모와 예측 및 동향 분석, 약제 클래스별(2018-2030년)
• 조직 플라스미노겐 활성화제(tPA)
• 항응고제
• 항혈소판약
• 항경련제
• 기타

제5장 뇌경색 치료 시장 : 유형별 비즈니스 분석

• 유형별 시장 점유율(2024년, 2030년)
• 유형 부문 대시보드
• 시장 규모와 예측 및 동향 분석, 유형별(2018-2030년)
• 허혈성 뇌졸중
• 출혈성 뇌졸중

제6장 뇌경색 치료 시장 : 유통 채널별 비즈니스 분석

• 유통 채널 시장 점유율(2024년, 2030년)
• 유통 채널 부문 대시보드
• 시장 규모와 예측 및 동향 분석, 유통 채널별(2018-2030년)
• 병원 약국
• 소매 약국
• 기타

제7장 뇌경색 치료 시장 : 지역별 추정 및 동향 분석

• 지역별 시장 점유율 분석(2024년, 2030년)
• 지역 시장 대시보드
• 시장 규모와 예측 동향 분석(2018-2030년)
• 북미
  • 국가별
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 국가별
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 국가별
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 국가별
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 참가자 개요
• 기업의 시장 포지셔닝 분석
• 기업 분류
• 전략 매핑
• 기업 프로파일, 상장 기업
  • Amgen Inc.
  • Pfizer Inc.
  • Novartis AG
  • Amneal Pharmaceuticals LLC
  • Sanofi
  • Abbott
  • Johnson &Johnson Services, Inc.
  • Bristol-Myers Squibb Company
  • DAIICHI SANKYO COMPANY
  • Otsuka Holdings Co., Ltd.

HBR

영문 목차

영문목차

Cerebral Infarction Treatment Market Growth & Trends:

The global cerebral infarction treatment market size is expected to reach USD 20.51 billion by 2030 and is projected to grow at a CAGR of 7.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of ischemic strokes, driven by an aging global population and increasing rates of lifestyle-related risk factors such as hypertension and diabetes, is a key factor in the expansion of the cerebral infarction treatment market.

According to a study published by the National Library of Medicine in March 2023, hemorrhagic stroke accounts for 10.0% to 20.0% of all strokes annually. The incidence varies significantly by region, with 8.0%-15.0% in the U.S., the UK, and Australia, and 18.0% to 24.0% in Japan and Korea. The rate of hemorrhagic stroke is notably higher in low- and middle-income countries, and among Asians. Furthermore, while stroke incidence is higher in men and increases with age, the global burden of hemorrhagic stroke is rising, particularly in African and Asian countries. Effective management of hypertension has been shown to reduce the incidence of intracerebral hemorrhage (ICH), though the fatality rate remains a concern, ranging from 25.0% to 30.0% in high-income countries and 30% to 48% in lower-income regions, highlighting disparities in critical care efficacy.

Technological advancements are significantly enhancing the treatment landscape for cerebral infarction. Innovations in thrombolytic therapies, such as tissue plasminogen activators (tPA), and development of mechanical thrombectomy devices have markedly improved patient outcomes. Moreover, the integration of artificial intelligence (AI) into diagnostic and treatment processes is revolutionizing stroke care. AI-driven algorithms now play a crucial role in predicting stroke risk and tailoring treatment strategies, which helps in personalizing care and improving overall efficacy. These advancements are not only improving the precision of treatments but also contributing to the broader adoption of advanced therapeutic options. Combined with increased investment in research and development, these technological strides are expected to drive significant growth in the cerebral infarction treatment market.

Cerebral Infarction Treatment Market Report Highlights:

• In 2024, the ischemic stroke segment held the largest share of 78.6% due to its high prevalence, technological advancements, and growing awareness of early intervention
• The tissue plasminogen activators (tPA) segment secured the largest revenue share of 39.2% in 2024, driven by its proven efficacy, widespread use, and crucial role in treating ischemic strokes
• In 2024, the hospital pharmacies segment dominated the cerebral infarction treatment market, capturing a substantial revenue share of 63.6%

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Type
  • 1.2.3. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Cerebral Infarction Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Cerebral Infarction Treatment Market: Drug Class Business Analysis

• 4.1. Drug Class Market Share, 2024 & 2030
• 4.2. Drug Class Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Billion)
• 4.4. Tissue Plasminogen Activators (tPA)
  • 4.4.1. Tissue Plasminogen Activators (tPA) Market, 2018 - 2030 (USD Billion)
• 4.5. Anticoagulants
  • 4.5.1. Anticoagulants Market, 2018 - 2030 (USD Billion)
• 4.6. Antiplatelets
  • 4.6.1. Antiplatelets Market, 2018 - 2030 (USD Billion)
• 4.7. Anticonvulsants
  • 4.7.1. Anticonvulsants Market, 2018 - 2030 (USD Billion)
• 4.8. Others
  • 4.8.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 5. Cerebral Infarction Treatment Market: Type Business Analysis

• 5.1. Type Market Share, 2024 & 2030
• 5.2. Type Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Billion)
• 5.4. Ischemic Stroke
  • 5.4.1. Ischemic Stroke Market, 2018 - 2030 (USD Billion)
• 5.5. Hemorrhagic Stroke
  • 5.5.1. Hemorrhagic Stroke Market, 2018 - 2030 (USD Billion)

Chapter 6. Cerebral Infarction Treatment Market: Distribution Channel Business Analysis

• 6.1. Distribution Channel Market Share, 2024 & 2030
• 6.2. Distribution Channel Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Billion)
• 6.4. Hospital Pharmacies
  • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Billion)
• 6.5. Retail Pharmacies
  • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Billion)
• 6.6. Other
  • 6.6.1. Other Market, 2018 - 2030 (USD Billion)

Chapter 7. Cerebral Infarction Treatment Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America Cerebral Infarction Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Regulatory Framework
    • 7.4.2.3. Competitive Insights
    • 7.4.2.4. U.S. Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Regulatory Framework
    • 7.4.3.3. Competitive Insights
    • 7.4.3.4. Canada Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Regulatory Framework
    • 7.4.4.3. Competitive Insights
    • 7.4.4.4. Mexico Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.5. Europe
  • 7.5.1. Europe Cerebral Infarction Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Framework
    • 7.5.2.3. Competitive Insights
    • 7.5.2.4. UK Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory Framework
    • 7.5.3.3. Competitive Insights
    • 7.5.3.4. Germany Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Regulatory Framework
    • 7.5.4.3. Competitive Insights
    • 7.5.4.4. France Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Regulatory Framework
    • 7.5.5.3. Competitive Insights
    • 7.5.5.4. Italy Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Regulatory Framework
    • 7.5.6.3. Competitive Insights
    • 7.5.6.4. Spain Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Regulatory Framework
    • 7.5.7.3. Competitive Insights
    • 7.5.7.4. Denmark Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Regulatory Framework
    • 7.5.8.3. Competitive Insights
    • 7.5.8.4. Sweden Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Regulatory Framework
    • 7.5.9.3. Competitive Insights
    • 7.5.9.4. Norway Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Framework
    • 7.6.2.3. Competitive Insights
    • 7.6.2.4. Japan Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory Framework
    • 7.6.3.3. Competitive Insights
    • 7.6.3.4. China Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory Framework
    • 7.6.4.3. Competitive Insights
    • 7.6.4.4. India Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.5. South Korea
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory Framework
    • 7.6.5.3. Competitive Insights
    • 7.6.5.4. South Korea Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.6. Australia
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Regulatory Framework
    • 7.6.6.3. Competitive Insights
    • 7.6.6.4. Australia Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Regulatory Framework
    • 7.6.7.3. Competitive Insights
    • 7.6.7.4. Thailand Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.7. Latin America
  • 7.7.1. Latin America Cerebral Infarction Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory Framework
    • 7.7.2.3. Competitive Insights
    • 7.7.2.4. Brazil Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Regulatory Framework
    • 7.7.3.3. Competitive Insights
    • 7.7.3.4. Argentina Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.8. MEA
  • 7.8.1. MEA Cerebral Infarction Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Regulatory Framework
    • 7.8.2.3. Competitive Insights
    • 7.8.2.4. South Africa Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Regulatory Framework
    • 7.8.3.3. Competitive Insights
    • 7.8.3.4. Saudi Arabia Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Regulatory Framework
    • 7.8.4.3. Competitive Insights
    • 7.8.4.4. UAE Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Regulatory Framework
    • 7.8.5.3. Competitive Insights
    • 7.8.5.4. Kuwait Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Amgen Inc.
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Pfizer Inc.
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Novartis AG
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Amneal Pharmaceuticals LLC
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Sanofi
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Abbott
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Johnson & Johnson Services, Inc.
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Bristol-Myers Squibb Company
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. DAIICHI SANKYO COMPANY
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Otsuka Holdings Co., Ltd.
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives

관련자료